These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 17392165

  • 1. Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms.
    Miwa T, Maldonado MA, Zhou L, Yamada K, Gilkeson GS, Eisenberg RA, Song WC.
    Am J Pathol; 2007 Apr; 170(4):1258-66. PubMed ID: 17392165
    [Abstract] [Full Text] [Related]

  • 2. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice.
    Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D, Werth VP, Madaio MP, Eisenberg RA, Song WC.
    Am J Pathol; 2002 Sep; 161(3):1077-86. PubMed ID: 12213736
    [Abstract] [Full Text] [Related]

  • 3. Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice.
    Miwa T, Zhou L, Maldonado MA, Madaio MP, Eisenberg RA, Song WC.
    J Immunol; 2012 Dec 01; 189(11):5434-41. PubMed ID: 23109726
    [Abstract] [Full Text] [Related]

  • 4. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice.
    Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS.
    J Immunol; 2001 May 15; 166(10):6444-51. PubMed ID: 11342671
    [Abstract] [Full Text] [Related]

  • 5. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
    Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS.
    Kidney Int; 2004 Jan 15; 65(1):129-38. PubMed ID: 14675043
    [Abstract] [Full Text] [Related]

  • 6. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan 15; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice.
    Stock AD, Wen J, Doerner J, Herlitz LC, Gulinello M, Putterman C.
    J Neuroinflammation; 2015 Nov 06; 12():205. PubMed ID: 26546449
    [Abstract] [Full Text] [Related]

  • 9. Nephritogenicity of the lprcg gene on the MRL background.
    Kimura M, Ogata Y, Shimada K, Wakabayashi T, Onoda H, Katagiri T, Matsuzawa A.
    Immunology; 1992 Jul 06; 76(3):498-504. PubMed ID: 1526655
    [Abstract] [Full Text] [Related]

  • 10. Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Faslpr Mice.
    Zhou Y, Chen H, Liu L, Yu X, Sukhova GK, Yang M, Kyttaris VC, Stillman IE, Gelb B, Libby P, Tsokos GC, Shi GP.
    J Immunol; 2017 Mar 01; 198(5):1846-1854. PubMed ID: 28093526
    [Abstract] [Full Text] [Related]

  • 11. C1q deficiency and autoimmunity: the effects of genetic background on disease expression.
    Mitchell DA, Pickering MC, Warren J, Fossati-Jimack L, Cortes-Hernandez J, Cook HT, Botto M, Walport MJ.
    J Immunol; 2002 Mar 01; 168(5):2538-43. PubMed ID: 11859149
    [Abstract] [Full Text] [Related]

  • 12. DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity.
    Miwa T, Zhou L, Tudoran R, Lambris JD, Madaio MP, Nangaku M, Molina H, Song WC.
    Mol Immunol; 2007 Jan 01; 44(1-3):139-46. PubMed ID: 16887189
    [Abstract] [Full Text] [Related]

  • 13. B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-b7.1/B7.2 blocking antibodies.
    Liang B, Gee RJ, Kashgarian MJ, Sharpe AH, Mamula MJ.
    J Immunol; 1999 Aug 15; 163(4):2322-9. PubMed ID: 10438978
    [Abstract] [Full Text] [Related]

  • 14. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
    Choi JY, Gao W, Odegard J, Shiah HS, Kashgarian M, McNiff JM, Baker DC, Cheng YC, Craft J.
    Arthritis Rheum; 2006 Oct 15; 54(10):3277-83. PubMed ID: 17009262
    [Abstract] [Full Text] [Related]

  • 15. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
    Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S.
    J Immunol; 2008 Jan 15; 180(2):1231-8. PubMed ID: 18178863
    [Abstract] [Full Text] [Related]

  • 16. Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice.
    Ju ZL, Shi GY, Zuo JX, Zhang JW, Jian Sun.
    Immunology; 2007 Feb 15; 120(2):281-9. PubMed ID: 17073941
    [Abstract] [Full Text] [Related]

  • 17. Absence of functional alternative complement pathway alleviates lupus cerebritis.
    Alexander JJ, Jacob A, Vezina P, Sekine H, Gilkeson GS, Quigg RJ.
    Eur J Immunol; 2007 Jun 15; 37(6):1691-701. PubMed ID: 17523212
    [Abstract] [Full Text] [Related]

  • 18. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 19. Langerhans Cells Maintain Local Tissue Tolerance in a Model of Systemic Autoimmune Disease.
    King JK, Philips RL, Eriksson AU, Kim PJ, Halder RC, Lee DJ, Singh RR.
    J Immunol; 2015 Jul 15; 195(2):464-76. PubMed ID: 26071559
    [Abstract] [Full Text] [Related]

  • 20. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice.
    Chesnutt MS, Finck BK, Killeen N, Connolly MK, Goodman H, Wofsy D.
    Clin Immunol Immunopathol; 1998 Apr 15; 87(1):23-32. PubMed ID: 9576007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.